Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 10/01/2014 20498_de.jpg

    HybridKnife – an instrument for future endoscopy

    Endoscopic and minimally invasive keyhole surgery is increasingly replacing open surgery. For many years now, patients have reaped the benefits of such treatment techniques, which are less stressful than open surgery and usually leave no scarring. People can leave hospital just a few days after treatment, which also contributes to cost savings in healthcare. Endoscopic submucosal dissection (ESD) is a new technique that enables the endoscopic…

    https://www.gesundheitsindustrie-bw.de/en/article/news/hybridknife-an-instrument-for-future-endoscopy
  • Press release - 12/10/2009 The photo shows Dr. Friesen holding a substance-containing vial.

    Methadone for treating brain tumours - finally an effective therapy in sight?

    Every year, around 5,500 people in Germany are diagnosed with malignant brain tumours. The chances of effectively treating patients with such tumours have barely improved over the last decades. A new therapeutic appears to be promising. Scientists at the Institute of Forensic Medicine at the University Hospital of Ulm have been able to show that methadone has the ability to combat brain tumours.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/methadone-for-treating-brain-tumours-finally-an-effective-therapy-in-sight
  • Press release - 21/09/2010 Immatics Logo

    immatics raises 54 million euros to advance its late stage clinical therapeutic cancer vaccine portfolio

    immatics biotechnologies GmbH a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer announced today that it has raised 53.8million in a Series C financing round. The new funds will allow the Company to finance the ongoing development of immatics existing pipeline of advanced therapeutic cancer vaccine candidates.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-raises-54-million-euros-to-advance-its-late-stage-clinical-therapeutic-cancer-vaccine-portf
  • Article - 06/05/2013 19644_de.jpg

    HeLa, a human bauplan in the Petri dish

    Scientists from EMBL have recently sequenced the genome of HeLa cells, which are the world’s most commonly used human cell line. They found that the HeLa genome and that of normal human cells reveal striking differences, caused by chromothripsis and other aberrations. Some evolutionary researchers believe that HeLa cells are developing a new human bauplan as they adapt to cultivation in the Petri dish.

    https://www.gesundheitsindustrie-bw.de/en/article/news/hela-a-human-bauplan-in-the-petri-dish
  • Press release - 28/05/2009 07777_de.jpg

    CureVac Begins Clinical Study with mRNA Vaccine

    CureVac GmbH announced that the Paul-Ehrlich-Institute, the German regulatory authority for medicinal products, has approved the Clinical Trial Application (CTA) to begin a Phase I clinical study with RNActive® derived mRNA vaccine CV9201. The vaccine will be tested in patients with advanced non-small cell lung cancer who have been pre-treated with different therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-begins-clinical-study-with-mrna-vaccine
  • Press release - 20/08/2012 17958_de.jpg

    Viruses with integrated gene switch

    Scientists of the German Cancer Research Center (DKFZ) with colleagues from the University of Konstanz have developed “RNA switches” which allow them to specifically turn on and off genes in viruses. This will help to enhance regulation of gene therapy and viral therapy of cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/viruses-with-integrated-gene-switch
  • Press release - 26/10/2020

    How to prevent the spread of tumor cells via the lymph vessels

    What role do the lymphatic vessels play in the metastasis of cancer cells? Scientists from the German Cancer Research Center and the Mannheim Medical Faculty of the University of Heidelberg developed a method to investigate this question in mice. The aim of the work was to identify new ways to block the dangerous colonization and spread of tumor cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-prevent-spread-tumor-cells-lymph-vessels
  • Press release - 05/01/2008

    Nycomed files marketing authorisation application for fentanyl spray

    Nycomed filed a marketing authorisation application with the European Medicines Agency for an intranasal fentanyl spray in Europe. If approved the centralised filing could allow Nycomed to be the first to enter the market in 29 European countries with the fentanyl spray.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-files-marketing-authorisation-application-for-fentanyl-spray
  • Article - 18/08/2014 Photo of a hand holding a syringe containing a dark fluid towards a naked upper arm.

    The use of human genes as medical products

    In contrast to medications used for treating disease, gene therapy does not use chemical agents to alleviate or cure disease symptoms. Instead, it involves the introduction of a normal copy of a mutated gene to restore the function of a protein. Gene therapy could also be described as a way of restoring the body’s self-healing process. It is an extremely smart idea that enables the sustainable treatment of diseases which cannot usually be…

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-use-of-human-genes-as-medical-products
  • Article - 30/06/2014 The photo shows Dr. Summerer and two of his colleagues in the laboratory.

    Targeting epigenetic DNA modifications for the diagnosis of cancer

    Epigenetic DNA modifications have been shown to play a role in carcinogenesis and are therefore a promising target for the early detection of cancer. Dr. Daniel Summerer and his research group at the University of Konstanz have developed a method that enables the direct and site-specific identification of epigenetic changes. The method represents a new approach in the field of epigenetic analysis as well as a major step towards simpler cancer…

    https://www.gesundheitsindustrie-bw.de/en/article/news/targeting-epigenetic-dna-modifications-for-the-diagnosis-of-cancer
  • Press release - 16/08/2012 17909_de.jpg

    Blood cancer cells initiate signalling cascade

    Researchers of the University of Freiburg have identified a new mechanism that causes immune cells to convert into malignant cancer cells. In Chronic Lymphocytic Leukaemia CLL one of the most common types of blood cancer in the Western world cells themselves carry the key for the pathogenic transformation the scientists report in the journal Nature. Understanding these underlying mechanisms could facilitate new therapies with reduced side…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/blood-cancer-cells-initiate-signalling-cascade
  • Article - 11/12/2008

    New drug that targets metastasing breast cancer in clinical phase III trial

    Protein kinases are a major focus of modern cancer research. Since it has become known that these enzymes play a role in the development of tumours, researchers around the world are concentrating on finding drugs to inhibit overactive protein kinases and prevent cancer cells from growing. One of these active substances is currently being tested at the Tumour Biology Centre in Freiburg as part of a worldwide phase III clinical trial.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-drug-that-targets-metastasing-breast-cancer-in-clinical-phase-iii-trial
  • Article - 31/05/2017 The tumours can be removed using peritonectomies with HIPEC.

    Peritoneal cancer – long-term survival with good quality of life

    Thanks to an innovative treatment procedure that has been in use since 2005, surgeons from Tübingen University Hospital have been able to prolong the survival of patients with peritoneal cancer and give them a higher quality of life. This is done using a technique based on complex surgery followed by immediate intraoperative local chemotherapy on the peritoneum.

    https://www.gesundheitsindustrie-bw.de/en/article/news/peritoneal-cancer-long-term-survival-with-good-quality-of-life
  • Article - 26/03/2012 Dr. Hesso Farhan with his group of researchers

    Cancer therapy targets secretory pathways

    Secretion is a fundamental cellular process. Defects in the secretory pathway have been associated with certain genetic diseases in which the maturation of proteins is disturbed. Non-genetic diseases such as metabolic disorders and cancer have also been linked to a defective secretory pathway. Dr. Hesso Farhan from the University of Konstanz and the Biotechnology Institute Thurgau BITg is investigating possible ways to counteract the development…

    https://www.gesundheitsindustrie-bw.de/en/article/news/cancer-therapy-targets-secretory-pathways
  • Article - 18/08/2014 The photo shows 7 staff members of VAXIMM GmbH.

    VAXIMM: Vaccines that impede cancer growth

    VAXIMM GmbH, a young biotechnology company from Mannheim, Germany, specialises in the development of vaccines for cancer treatment. The company’s first product candidate, VXM01, is a live oral vaccine that targets the VEGFR-2 receptor and hence the blood supply of tumours. VXM01 is currently undergoing clinical testing in pancreatic cancer patients.

    https://www.gesundheitsindustrie-bw.de/en/article/news/vaximm-vaccines-that-impede-cancer-growth
  • Press release - 22/06/2017 dkfz-Zucker-MRT.jpg

    MRI without contrast agents? Yes, with sugar!

    Scientists from the German Cancer Research Center (DKFZ), in collaboration with colleagues from Heidelberg University Hospital, have been able to visualize brain cancer using a novel MRI method. They use a simple sugar solution instead of conventional contrast agents, which can have side effects in the body.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/mri-without-contrast-agents-yes-with-sugar
  • Press release - 04/03/2009

    Plant Pathogen Yields Substance to Fight Neuroblastoma

    Drug treatment of neuroblastoma, a tumor of the nervous system in children, poses major problems. Therefore, scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have been searching for substances that are suitable as a basis for developing better drugs. Now they have found a candidate: HC-toxin, which is isolated from a fungal plant pathogen. The substance from the maize pathogen reprograms neuroblastoma cells…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/plant-pathogen-yields-substance-to-fight-neuroblastoma
  • Press release - 23/01/2012 16253_de.jpg

    Rigged to explode?

    An inherited mutation in a gene known as the guardian of the genome is likely the link between exploding chromosomes and some particularly aggressive types of cancer, scientists at the European Molecular Biology Laboratory (EMBL), the German Cancer Research Centre (DKFZ) and the University Hospital, all in Heidelberg, Germany, have discovered. Their study, published online in Cell, also presents the first whole genome sequence of a paediatric…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/rigged-to-explode
  • Article - 28/04/2014 21397_de.jpg

    Sciomics: antibody microarrays and their broad range of applications

    Sciomics GmbH is a start-up biotech from Heidelberg with a special focus on protein microarrays. Sciomics produces complex, high-density antibody microarrays for cancer-relevant proteins and offers services for medical research, diagnostics and the industry, including biomarker screening, the verification of biomarker candidates, the analysis and localization of drug targets and their signalling pathways as well as the characterization of…

    https://www.gesundheitsindustrie-bw.de/en/article/news/sciomics-antibody-microarrays-and-their-broad-range-of-applications
  • Article - 29/11/2010 12950_de.jpg

    CYP2D6 and the oestrogen receptor

    The medicinal adjuvant therapy of breast cancer is a good example of how important it is being aware that different patients metabolise drugs differently. This knowledge plays a key role in the prescription of effective drugs at the correct dose and in preventing adverse reactions and interactions with concomitant drugs.

    https://www.gesundheitsindustrie-bw.de/en/article/news/cyp2d6-and-the-oestrogen-receptor
  • Dossier - 15/03/2010 09298_de.jpg

    Vaccine development

    As the recent discussion on the pros and cons of swine flu vaccinations has shown vaccinations are not very popular in Germany. However people tend to forget that no other medical development has helped people to the same extent as immunisation with vaccines has done. Examples include the discovery of the cow pox vaccination by Edward Jenner in 1796 and all the programmes that have been set up by the Global Alliance for Vaccines and Immunisation…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/vaccine-development
  • Press release - 02/11/2020

    Juvenile myelomonocytic leukemia: International classification model allows for customized treatment

    Juvenile myelomonocytic leukemia (JMML) is a rare blood cancer of early childhood. Previous research activities have shown that JMML patients can be divided into three groups based on certain genetic markers, DNA methylation. Depending on the subgroup, statements can be made about the course of the disease.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/juvenile-myelomonocytic-leukemia-international-classification-model-allows-customized-treatment
  • Press release - 16/02/2010 Logo DKFZ, blue letters "DKFZ"

    He Who Dares Wins – Million Euro Funding for DKFZ Researcher

    The European Research Council will provide funding of 2.4 million euro over the next four years to support a research project of Christof Niehrs at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ). Niehrs investigates the processes of reactivation of silenced genes in cells. Disruption of this mechanism can cause cancer and other diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/he-who-dares-wins-million-euro-funding-for-dkfz-researcher
  • Article - 05/06/2008

    CureVac: partnership with University of Florida,

    CureVac GmbH has entered into a partnership with the Department of Urology University of Florida Gainesville U.S. to jointly advance its lead candidate CV9103 into the clinical development. The alliance covers preclinical studies and a US phase III trial.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-partnership-with-university-of-florida
  • Press release - 24/07/2012 17760_de.jpg

    Tailor-made viruses for enhanced cancer therapy

    Parvoviruses specifically kill cancer cells and are already in the clinical trial stage for treating malignant brain tumors. However, as they can also infect normal cells - without doing any harm to them - a large portion of viruses is lost during therapy. Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now modified parvoviruses in such a way that they initially lose their ability to infect cells. In…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tailor-made-viruses-for-enhanced-cancer-therapy

Page 8 / 30

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 30
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2021
Website address: https://www.gesundheitsindustrie-bw.de/en/search